UK drug update

Published: 22-Oct-2001
Regulatory


Schering Health Care has launched MabCampath infusion. The product contains 10mg/ml of the monoclonal antibody alemtuzumab.

Dominion Pharma has marketed 50mg capsules of the opiate analogue tramadol hydrochloride.

Roche Products has made available 250mg film-coated tablets of Viracept, containing the protease inhibitor nelfinavir.

Astra Zeneca has launched Zomig Rapimelt. The dispersible tablets contain 2.5mg of the 5HT1-agonist zolmitriptan.

Lagap Pharmaceuticals has produced 200mg and 400mg tablets of the 4-quinolone ofloxacin.

APS/Berk has brought out 200mg and 400mg tablets of the 4-quinolone ofloxacin.

Generics (UK) has made available 2.5mg and 5mg tablets of the thiazide diuretic bendrofluazide; 2.5mg and 5mg tablets of the sulphonylurea glibenclamide; and 25mg tablets and 50mg capsules of the narcotic analgesic pentazocine.

CeNeS Pharmaceuticals has introduced Xefo tablets and injection. The tablets contain 4mg or 8mg of the non-steroidal antiinflammatory drug lornoxicam and the injection contains 8mg/2ml lornoxicam.

Chauvin Pharmaceuticals has marketed Virgan eye gel. The product contains 0.15% of the DNA polymerase inhibitor ganciclovir.

See more

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

Read more
New SOLAR CEMNEX analyser offers advanced compliance and connectivity features

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision

Partnership delivers compliance confidence, efficiency gains and reduced waste
Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Subscribe now